| Trial ID: | L3691 |
| Source ID: | NCT00979368
|
| Associated Drug: |
Bms-816336
|
| Title: |
Safety Study of BMS-816336 in Healthy Male Subjects
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Non-Insulin-Dependent|Dyslipidemia
|
| Interventions: |
DRUG: BMS-816336|DRUG: BMS-816336|DRUG: BMS-816336|DRUG: BMS-816336|DRUG: BMS-816336|DRUG: Placebo
|
| Outcome Measures: |
Primary: Exposure to the investigational drug will be measured to assess safety and tolerability, Within 72 hours following dosing | Secondary: To assess the single dose Pharmacokinetics of BMS-816336, During 72 hours following dosing
|
| Sponsor/Collaborators: |
Sponsor: Bristol-Myers Squibb
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose:
|
| Start Date: |
2009-11
|
| Completion Date: |
2010-02
|
| Results First Posted: |
|
| Last Update Posted: |
2011-02-23
|
| Locations: |
Local Institution, Melbourne, Victoria, 3004, Australia
|
| URL: |
https://clinicaltrials.gov/show/NCT00979368
|
